Catalyst Dossier · compiled by CeliA 🧫
MiNK Therapeutics, Inc. (INKT)
Biological Products, (No Diagnostic Substances) · market cap $11M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-06-15 (est.)
Phase 2
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
MiNK Therapeutics (INKT) is a micro-cap biological products company with 23 employees and a $53M market cap, developing agenT-797, an iNKT cell therapy currently in Phase 2 for pneumonia. The company carries $9.5M in cash (~16.5 months runway) and has generated no meaningful revenue since 2022, with cumulative losses exceeding $100M over the tracked period.
The catalyst path
- 2027-06-15 (est.)Phase 2 · agenT-797imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| agenT-797 | Phase 2 | Pneumonia |
Price & technical context
3-month
-0.4%
6-month
+1.5%
12-month
-20.0%
52-wk range
$8.56–$17.50
vs 50-day MA
-0.3%
vs 200-day MA
-1.6%
Realized vol
74.2%
Max drawdown
-86.7%
Daily closes through 2026-08-12. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for INKT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.